These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 19720635

  • 1. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 2. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 3. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Nov; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 4. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K.
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [Abstract] [Full Text] [Related]

  • 5. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Aug; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 6. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 7. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Jan; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 8. Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study.
    IONA Study Group.
    Am Heart J; 2005 Oct; 150(4):689. PubMed ID: 16209965
    [Abstract] [Full Text] [Related]

  • 9. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K.
    Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
    [Abstract] [Full Text] [Related]

  • 10. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators.
    Lancet; 2008 Sep 06; 372(9641):807-16. PubMed ID: 18757088
    [Abstract] [Full Text] [Related]

  • 11. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 12. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 13. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML, EUROPA investigators.
    Int J Cardiol; 2007 Sep 14; 121(1):57-61. PubMed ID: 17270296
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L.
    Eur J Heart Fail; 2010 Jan 14; 12(1):75-81. PubMed ID: 19892778
    [Abstract] [Full Text] [Related]

  • 15. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, HOPE Investigators.
    Circulation; 2004 Sep 14; 110(11):1413-7. PubMed ID: 15353497
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 17. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ, Lamas GA, Gordon D, Bernstein V, Pfeffer MA, Survival and Ventricular Enlargement Trial.
    Am Heart J; 2004 Aug 10; 148(2):356-64. PubMed ID: 15309009
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M, Borer JS, Tardif JC.
    Cardiology; 2009 Aug 10; 114(2):116-25. PubMed ID: 19468225
    [Abstract] [Full Text] [Related]

  • 19. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 10; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 20. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA.
    Arch Intern Med; 2004 Nov 08; 164(20):2273-9. PubMed ID: 15534166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.